Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $430 from $426 and keeps a Sector Perform rating on the shares. The FDA recently approved Vertex’s vanzacaftor triple therapy for the treatment of cystic fibrosis, CF, in patients 6 years of age and older, which was widely expected given the “strong” clinical data, the analyst tells investors. Rollout for the drug should be rapid, but switching dynamics with Trikafta, the company’s other drug for CF, could take some time given its “excellent clinical profile,” the firm adds. Overall, the approval is a win for Vertex and should allow the company to maintain its leadership position in CF, Scotiabank concludes.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex black box warning for Alyftrek ‘somewhat a surprise,’ says Barclays
- Vertex Pharmaceuticals price target lowered to $500 from $503 at JPMorgan
- Vertex Pharmaceuticals Gains FDA Approval for Cystic Fibrosis Drug
- Vertex announces FDA approval of Alyftrek
- Vertex announces FDA exands approval for Trikafta